$REGN Headlines Regeneron skids on shortfall in Eylea

New Post Public Reply Private Reply Replies (0) Message Board

Nov 15, 2014 at 6:30 AM

$REGN Headlines

Regeneron skids on shortfall in Eylea sales 11:15 a.m. Nov. 4, 2014 - Russ Britt
Regeneron Pharmaceuticals shares rise 8% 8:31 a.m. Oct. 17, 2014 - Sue Chang
10 rock-solid stocks for conservative investors 8:51 a.m. Sept. 17, 2014 - Philip van Doorn
S&P 500 nails the breakout point 9:35 a.m. Sept. 8, 2014 - Michael Ashbaugh
Regeneron shares run up 4.8% to lead S&P 500 gainers 8:34 a.m. Sept. 2, 2014 - Tomi Kilgore
Small health companies see large gains on a big earnings day 4:34 p.m. July 30, 2014 - Russ Britt
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 3:26 p.m. July 30, 2014 - Sue Chang
Edwards, Hospira rise as health-care companies see strong earnings 12:08 p.m. July 30, 2014 - Russ Britt
Regeneron shares jump after cholesterol drug meets test goals 10:16 a.m. July 30, 2014 - Russ Britt
Regeneron Pharmaceuticals jumps 7.7% 8:32 a.m. July 30, 2014 - Sue Chang
Dow ends at record high close but still shy of 17,000: Stock market live blog recap 3:04 p.m. July 1, 2014 - blogs.marketwatch.com
Twitter gains on new CFO; GM sales up in June 1:29 p.m. July 1, 2014 - Sue Chang
Oracle slides on disappointing results; CarMax soars 3:17 p.m. June 20, 2014 - Sue Chang
Maybe Amazon will unveil a toaster today 7:08 a.m. June 18, 2014 - Marek Fuchs
Twitter rallies ahead of earnings; 3D Systems retreats 2:49 p.m. April 29, 2014 - Sue Chang
Intuitive Surgical slumps; Facebook extends rally 2:41 p.m. April 9, 2014 - Sue Chang
44 stocks on takeover target radar: Morgan Stanley 11:48 a.m. March 25, 2014 - blogs.marketwatch.com
First Solar, H-P, Symantec are stocks to watch 3:16 p.m. March 21, 2014 - Sue Chang
First Solar extends winning streak; Symantec plunges 2:07 p.m. March 21, 2014 - Sue Chang
Nasdaq falls for 4th day in row; Dow, S&P slip for 2nd day: stock market live blog recap 2:51 p.m. March 11, 2014 - blogs.marketwatch.com

Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences 9:23 a.m. Nov. 14, 2014 - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (REGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Nov. 14, 2014 - Zacks.com
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals 7:02 a.m. Nov. 13, 2014 - Investors Business Daily
3 Stocks Moving The Drugs Industry Upward 12:25 p.m. Nov. 12, 2014 - TheStreet.com
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog 11:00 a.m. Nov. 12, 2014 - Zacks.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Nov. 12, 2014 - Zacks.com
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14) 5:20 a.m. Nov. 12, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names 8:59 p.m. Nov. 11, 2014 - TheStreet.com
Stock Market News for November 11, 2014 - Market News 10:10 a.m. Nov. 11, 2014 - Zacks.com
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN) 9:51 a.m. Nov. 11, 2014 - TheStreet.com
Sanofi/Regeneron asthma drug successful in Phase 2 trial 7:44 a.m. Nov. 11, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: VZ, MRK, REGN 10:59 a.m. Nov. 10, 2014 - TheStreet.com
Regeneron updates guidance after Q3 results 11:09 a.m. Nov. 6, 2014 - Seeking Alpha
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis 8:32 a.m. Nov. 6, 2014 - Seeking Alpha
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way 11:24 a.m. Nov. 5, 2014 - TheStreet.com
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog 9:46 a.m. Nov. 5, 2014 - Zacks.com
Jazz Beats And Raises Views; Regeneron Misses In Q3 6:02 p.m. Nov. 4, 2014 - Investors Business Daily
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog 4:30 p.m. Nov. 4, 2014 - Zacks.com
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2014 Conference Call Transcript 4:16 p.m. Nov. 4, 2014 - TheStreet.com
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter 9:51 a.m. Nov. 4, 2014 - Investors Business Daily

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma 1:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Regeneron Reports Third Quarter 2014 Financial and Operating Results 6:30 a.m. Nov. 4, 2014 - PR Newswire - PRF
Regeneron Announces Upcoming 2014 Investor Conference Presentations 4:01 p.m. Nov. 3, 2014 - PR Newswire - PRF
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter 9:15 a.m. Nov. 3, 2014 - PR Newswire - PRF
New Solution for Patients, Quarterly Financial Results, Clinical Study Initiation, Merger Updates, and Product Launch - Research Reports on CVS, Valeant, Regeneron, Allergan and Agilent 9:20 a.m. Oct. 23, 2014 - PR Newswire - PRF
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma 9:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis 7:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study 7:00 a.m. Oct. 17, 2014 - PR Newswire - PRF
Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year 2:00 p.m. Oct. 16, 2014 - PR Newswire - PRF
Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments 8:30 a.m. Oct. 16, 2014 - PR Newswire - PRF
Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014 4:01 p.m. Oct. 15, 2014 - PR Newswire - PRF
Critical Alerts For ITT Education, EOG Resources, Mobileye NV, CBS and Regeneron Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Dividend, Regulatory Warning, Board Statements, and Technical Updates - Research Reports on Regeneron, CVS Health, Valeant, Allergan and Jazz 9:15 a.m. Oct. 7, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) 4:58 p.m. Oct. 6, 2014 - PR Newswire - PRF
Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 1:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Regulatory Approvals, Senior Notes Redemption, and Technical Updates - Research Reports on Tekmira, Regeneron, Valeant, Teva and United Therapeutics 9:20 a.m. Sept. 25, 2014 - PR Newswire - PRF
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan 2:30 a.m. Sept. 22, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema 7:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
Biotech Stocks Under Review -- Keryx Biopharma, Sangamo BioSciences, Regeneron Pharma, Sunesis Pharma, and Idera Pharma 9:10 a.m. Sept. 9, 2014 - PR Newswire - PRF
Critical Alerts For Rocket Fuel, General Motors, International Business Machines, Google and Regeneron Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Sept. 8, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ontario Fuels Life Sciences Growth with $1.7M Boost

A Jolt for Ontario's Life Sciences Sector Ah, there's fresh energy in the air up north, folks. Ontario's dishing out a solid $1.7 million to give Piramal Pharma Solutions' Aurora facility a serious facelift. This isn't just about shiny new labs. It's about staking a claim, saying, "We're serious players on the global stage." They're not just upgrading infrastructure...

Survey Says 92% Report Better Life Post-Rehab

92% Say Life Improves After TranquilHearts' Treatment It's not every day you see 92% of folks claiming something actually worked for them, huh? That's exactly the kind of figure TranquilHearts Rehab's alumni claimed in their recent survey about improved quality of life post-treatment. But let's not get ahead of ourselves with high-fives and celebration just yet. Here's...

Sarwant Singh Propels Frost & Sullivan's AI Ambitions

A Veteran Strategist Returns to the Fold Sharp moves in the corporate world don't always grab headlines, but sometimes you’ve got to stop and consider the buzzworthy comebacks. Keep your eyes peeled for Sarwant Singh's return to Frost & Sullivan, a noteworthy shift that’s shaping the landscape of digital strategies and beyond. Turning Up the Heat on Digital Innovation...

Alta's SoMi Walk: Luxury Student Housing on Sale

Eyeing the Future in South Miami Real Estate Well, folks, things are heating up in South Miami’s real estate scene, and it’s not something investors want to snooze through. Alta Development, with its decades-long track record, has hurled SoMi Walk into the market ring. This isn't just another dime-a-dozen project. It's a behemoth—standing at 16 stories and posing as...

Caracal's New Baltimore Hub: A Green Leap in Healthcare

Recycling Revolution: Caracal's Bold Move in Baltimore In a world drowning in waste, Caracal Products & Services is making a stand—this time in Baltimore. This latest venture isn't just another warehouse on the map; it’s a beacon for sustainable practices in healthcare recycling. An industrial complex at 2-6 Alco Place now houses Caracal's 9,000-square-foot hub, a...

Bryan Park's Vision Drives Footprints' Surging Growth

An Airman’s Mission of Building Legacies When you think of flooring, 'admired CEOs' probably don’t top the list. Yet here’s Bryan Park, an ex-Air Force veteran, shaking things up and earning a nod from the Denver Business Journal. Named one of the Most Admired CEOs of 2026, Park has taken what began as a small flooring operation and turned it into a national...

Joe Richardson's Impact Reaches New Heights in 2026

They don't hand out "Attorney of the Year" awards to just anyone. Joe Richardson snagged this title from the Richard T. Fields Bar Association not just because he's part of McCune Law Group, but because he's been shaking up the legal arena with his advocacy and leadership. Let's peel back why this matters not only within his circles but for the broader legal community...

El Mansouri Becomes Morocco's First Female PM

Breaking Barriers: El Mansouri's Historic Appointment Fatima Ezzahra El Mansouri is now steering the ship as Morocco's first female Prime Minister, a milestone that's taken far too long to reach. After the dust settled from the September 23 legislative elections, El Mansouri emerged from the Authenticity and Modernity Party (PAM) with 97 seats in tow. It's a pivotal...

Pathology Ventures: Industry Veteran Takes the Helm

What's Brewing with Pathology Ventures? Amidst the bustling landscape of healthcare, Pathology Ventures, LLC shakes things up by appointing Dominic Stockey as their Executive Vice President. Now, buckle up because Stockey isn’t your average Joe. He’s kicking it up a notch by spearheading sponsor and industry partnerships at this physician-founded network. His turf?...

Oak Farms Invests in Texas Schools and Students

Putting Money Where Their Roots Are You have to hand it to Oak Farms; when they say they're rooted in Texas, they actually back it up with some cold, hard cash. They've lined up $27,500 for schools and students across the state. That's the kind of talking I like to see—straight from the brand to the community ledger. No fluff, just good old-fashioned giving in the form...